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Abstract
Because fibroblast growth factors (FGFs) modulate important
functions of endothelial cells (EC) and smooth muscle cells
(SMC), we studied FGF expression in human vascular cells
and control or atherosclerotic arteries. All cells and arteries
contained acidic(a) FGFand basic (b)FGF mRNA. Northern
analysis detected aFGFmRNAonly inoneoffivecontrolarter-
ies butin all five atheroma tested, while levels ofbFGF mRNA
did not differ among control (n = 3) vs. plaque specimens (n
= 6). Immunolocalization revealed abundant bFGF protein in
control vessels (n = 10), but little in plaques (n = 14). In
contrast, atheroma (n = 14), but not control arteries(n = 10),
consistently exhibited immunoreactive aFGF, notably in neo-
vascularized and macrophage-rich regions of plaque. Because
macrophagescolocalizedwithaFGF,wetestedhumanmonocyt-
oid THP-1 cells and demonstrated accumulation of aFGF
mRNA during PMA-induced differentiation. We also exam-
ined the expression of mRNA encoding FGF receptors
(FGFRs). All cells and arteries contained FGFR-1 mRNA.
Only SMC and control vessels had FGFR-2 mRNA, while EC
and somearteries contained FGFR4 mRNA. Therelative lack
of bFGF in plaques vs. normal arteries suggests that this
growth factor may not contribute to cell proliferation in ad-
vanced atherosclerosis. However, aFGF produced by plaque
macrophages may stimulate the growth ofmicrovessels during
human atherogenesis. (J. Clin. Invest. 1993. 92:2408-2418.)
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Introduction
Fibroblast growth factors (FGFs) exertwide-rangingeffects on
various cell types( 1-4). Invitro FGFs can stimulate prolifera-
tion, morphologic changes, and migration ofvascularEC' and
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SMC( 1-4). Invivothesegrowthfactorsparticipateindevelop-
ment ( 1-4), vasculogenesis (5), angiogenesis (6, 7), and
wound healing (6). Acidic FGF (aFGF) and basic FGF
(bFGF), also known as FGF-l and FGF-2, respectively (8),
are the best characterized membersofthe FGFfamily. A com-
plex superfamily ofcell surface receptors with tyrosine-kinase
activity mediates FGFs' effects on target cells (9, 10).
Recent studies support the involvement of aFGF and
bFGF in vascular pathobiology. Animal experiments have es-
tablished thatthesegrowth factors can fosterre-endothelializa-
tion ( 11, 12), mediate SMC replication (12-14), and stimu-
late formation ofvasa vasorum ( 14) in balloon-injured arter-
ies. Although vascular EC and SMC can both produce and
respondtoaFGFandbFGFinvitro, informationisincomplete
regarding expression and localization ofthese growth factors
andtheirreceptorsin eithernormal(15) oratherosclerotic( 15,
16) human arteries. This study explored these issues.
We documented differential patterns ofexpression ofFGF
family members and oftheir receptors in cultured human EC
andSMCandinatheroscleroticandcontrolarteries.Inparticu-
lar, we foundincreasedlevelsofaFGFmRNAinhumanather-
oma compared to nonatherosclerotic arteries and association
ofaFGFproteinwithplaquemicrovesselsandmacrophages. In
contrast, atheroma contained less immunoreactive bFGFpro-
tein than control arteries.
Methods
Cellculture. Human umbilical vein ECandaortic SMCweregrown as
previously described ( 17). Human embryonal carcinoma cells
(TERA-2), purchased from the American Type Culture Collection,
Rockville, MD, were grown in medium 199 with 10% FCS, 100 U/ml
penicillin, 100 gg/ml streptomycin, and 0,25 ug/ml amphotericin B
(complete M199). Human skin fibroblasts (GM2037), purchased
from the Human Genetic MutantCell Repository, Camden, NJ, were
grown as previously described ( 18). Human monocytes were isolated
from leukocyte-rich fractions collected after leukapheresis from
healthy donors. Mononuclear cells were layered onto Ficoll hypaque
(Pharmacia LKB Biotechnology, Piscataway, NJ) and separated by
centrifugation (2,500 rpm, 25 min). The mononuclear cell band was
washed twice with HBSS without Ca2' andMg2+, resuspended in me-
dium RPMI 1640 with L-glutamine, 10% FCS, 25 mM Hepes, and 1%
penicillin-streptomycin (complete RPMI) and permitted to adhere to
polystyrene flasks. After2 h, nonadherent cellswere removedbywash-
ing gently three times with HBSS and medium was replaced. Mono-
1. Abbreviations used in this paper: aFGF, acidic fibroblast growth
factor; bFGF, basic fibroblast growth factor; complete M199, medium
199 with 10% FCS, 100U/mlpenicillin, 100,g/mlstreptomycin, and
0.25 ug/ml amphotericin B; complete RPMI, medium RPMI 1640
with L-glutamine, 10% FCS, 25 mM Hepes, and 1% penicillin-strepto-
mycin; EC, endothelial cells; FGFR, fibroblastgrowth factorreceptor;
GITC, guanidinium isothiocyanate; RT, reverse transcription;, SMC,
smooth muscle cells; TBS, tris-buffered saline.
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Gene Sense Antisense Ref
bp
aFGF GCTGCTGAGGCCATGGCTGAA ACAGATCTCTTTAATCAGAAGAGACTG 489 40
bFGF GGAGTGTGTGCTAACCGTTACCTGGCTATG TCAGCTCTTAGCAGACATTGGAAGAAAAAG 243 41
FGF-3 ATGGGCCTAATCTGGCTGCTACTG CAAACTCGCACTCGGCGCTGTAGT 349 42
FGF-4 GACTACCTGCTGGGCATCAAGCGG GATGAACATGCCGGGGTACTTGTA 314 43
FGF-5 TCCAGCAGCAGACAGAGCAGCAGT TGAGTTGGTATTTTTCCGAGGTGC 641 44
FGF-6 AGGCACCCGTGCCAACAACACGCT TGACAGTCATGATCGGGGACACCT 484 45
FGF-7 CTTTGCTCTACAGATCATGCTTTC TTGCCATAGGAAGAAAGTGGGCTG 542 34
FGFR-l AAGGACAAACCCAACCGTGTGACC CCCAAAGTCTGCTATCTTCATCAC 425 46
FGFR-2 CTGTGCCGAATGAAGAACACGACC CCCAAAGTCTGCTATCTTCATCAC 743 47
FGFR-3 TGAGGACACAGGTGTGGACACAGG TCTGCCGGATGCTGCCAAACTTGT 295 36
FGFR-4 CTCGCCGGCCTCGTGAGTCTAGAT CCCAAAGTCTGCTATCTTCATCAC 560 37
Actin ACCCTGAAGTACCCCAT TAGAAGCATTTGCGGTG 931 48
Primer pairs were designed to amplify selectively a specific fragment ofthe target sequence investigated. bp refers to the size ofthe PCR product
expected and observed for each primer pair. Primer sequences are 5' to 3'.
cytes, identified by positive staining with EBM-11 antibody (1:4,000
dilution; Cat. no. M718; Dako Corp., Carpinteria, CA), were cultured
and used at various time points after isolation. Cells of the human
monocytoid leukemia cell line THP-I (19), adapted to long-term cul-
ture, were passaged in complete RPMI at a concentration of2 x 105
cells/ml, butplated athigherdensity(6 X I05cells/ml) forexperimen-
tal use. All components used in tissue culture media were tested for
endotoxin contamination using the chromogenic Limulus amebocyte
lysate assay (QCL 1,000; M.A. Bioproducts, Walkersville, MD). All
medium constituents yielded a final concentration of endotoxin less
than 40 pg/ml.
Arterialtissue. 14carotid plaqueswere obtainedatendarterectomy
andprocessed within 2 haftersurgery. Eachspecimen wasrinsedtwice
in cold PBSto minimizeblood residue, then aportion wassnap-frozen
in optimal cuttingtemperature tissueprocessing medium (OCT; Miles
Diagnostics, Elkhart, IN) for immunohistochemical study and the re-
maining part was flash-frozen in liquid nitrogen and stored at -80°C
for RNA isolation. Although thestudy did notinclude heavilycalcified
plaques, all atherosclerotic samples studied contained focal calcifica-
tions atmicroscopic examination. 10 control human arteries (4 aortas,
1 coronary, 1 subclavian, and 4 carotid arteries) were obtained from
the New England Organ Bank orthe Department ofSurgery and han-
dled similarly. Control arteries had a grossly normal appearance. At
microscopic examination, six of them exhibited a degree of intimal
thickening within normal limits for human arteries.
RNA isolationfrom culturedcellsandtissuesamples. Inshort-term
experiments human monocytes and THP-1 cellswere stimulated with:
PMA, 25 nM (cat. no. P-8139, Sigma Chemical Co., St. Louis, MO);
palmitoyl L-alpha-lysophosphatidylcholine, 100 MM (cat. no. L-5254,
SigmaChemicalCo.); IFN-gamma, 500 U/ml(R&DSystems, Minne-
apolis, MN); LPS from Escherichia coli 055:B5, 10 ng/ml (cat. no.
L-2880, SigmaChemical Co.), andPDGF-BB, 10 ng/ml (Amgen Inc.,
ThousandOaks, CA). Cellswere harvested after0, 2, 6, 10, 24, and 72
hoftreatment. Inalongertimecoursestudy,THP-I cellswerecontinu-
ously stimulated with PMA, 100 nM for 4, 7, 14, and 17 d. Unstimu-
lated control cellswere harvested atday0and 17. Duringthe course of
long-term experiments culture medium, with or without addition of
PMA, was replaced every other day. Total RNA from TERA-2 cells
and human skin fibroblasts wasprepared asdescribed (17). SMCwere
growth-arrested for 48 h (20), stimulated for 6 h with PMA (25 nM),
and extracted in GITC (21). Tissue samples were homogenized in
GITC and total RNA extracted (21). RNA concentration was calcu-
lated from the absorbance at 260 nm. All RNA samples contained
intact rRNA and lacked genomic DNA as evaluated by ethidium bro-
mide staining ofagarose-formaldehyde gels. Other RNA samples (hu-
man brain, lung, skeletal muscle) used as positive controls in reverse
transcription (RT)-PCR reactions, were purchased from Clontech,
Palo Alto, CA.
Northern blot analysis. Equivalent amounts ofRNA (10 or 15 gg,
depending on the experiment) were separated on a 1.2% agarose gel
containing 2.2 M formaldehyde. Gels were stained with ethidium bro-
mide to verify loading ofsimilar amounts ofundegraded RNA. After
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Figure 1. EC and SMC
expressaFGF, bFGF,
and FGF-5 mRNA in
vitro. SMC also express
FGF-7 mRNA. This
figure shows results of
RT-PCR analysis at 35
cycles. We detected ex-
pression of aFGF,
bFGF, and FGF-5
mRNA in human EC
in vitro. Aortic SMC
expressed aFGF, bFGF,
FGF-5, and FGF-7
mRNA. Sources of pos-
itive control RNA were:
human brain foraFGF
and bFGF; TERA-2
cells for FGF4; human
skin fibroblasts for
FGF-5 and FGF-7; and
skeletal muscle for
FGF-6.
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Figure 2. Control and atherosclerotic arteries express aFGF, bFGF,
and FGF-7 mRNA. Thisfigure shows results ofRT-PCRanalysis at
35 cycles. All control and atherosclerotic arteries contained aFGF
mRNA; they also contained inconsistent levels ofbFGF mRNA.
Neither control nor atherosclerotic plaques contained FGF-5 mRNA,
although this transcript was detected in cultured aortic SMC (Fig.
1). Both control and atherosclerotic arteries contained FGF-7
mRNA. Sources ofpositive control RNA were: human arterial SMC
foraFGF, bFGF, FGF-5, andFGF-7; TERA-2 cells forFGF-4; and
skeletal muscle for FGF-6. Identical volumes ofthe reaction mixture,
butwithoutaddition ofcDNA, served asnegative controls. PCR re-
actions using beta-actin specific primers demonstrated that equal
amounts ofcDNA had been used and similarly amplified.
capillary transfer to nylon membranes(Hybond-N; Amersham Corp.,
Arlington Heights, IL), RNA wasimmobilizedbyshort-wave UVirra-
diation (Stratalinker; Stratagene Corp., La Jolla, CA). Hybridization
probes were labeled with [alpha-32P]dCTP (New England Nuclear,
Boston, MA)byrandompriming; freenucleotideswereremovedusing
aSephadex G-50 column(Worthington Biochemical Corp., Freehold,
NJ). Probes had specific activities of 2-5 X 108 cpm/Mg. The DNA
probeswere: (a)forhumanaFGF, a2.2-kbEcoRIfragmentofpDH15,
purchased from American Type Culture Collection; (b) for bovine
bFGF, a 1.4-kbEcoRIfragmentofpJJI 1 (giftofDr. J.Abraham, Scios
Nova Inc., Mountain View, CA); (c) for human FGFR-1, a 0.7-kb
EcoRI/HindIII fragment offlg PCR-R (gift of Dr. M. Jaye, Rhone-
Poulenc RorerPharmaceuticals, Collegeville, PA). Hybridization and
washing conditions were as reported (19).
Reversetranscription (RT). ForRT, 1 ugoftotal RNA from THP-
I cells was incubated in a I0-,Ml reaction mixture as previously de-
scribed(22). Forthe other RNAsamplesfromtissues orcultured cells
1 Mg of total RNA was incubated at 370C for I h in 50 Ml reverse
transcriptase buffer (50 mM Tris-HCI, pH 8.3; 10 mM DTT; 75 mM
KCI; 3 mM MgC12; 0.4 mM deoxyribonucleotide triphosphates) con-
taining 20 U of RNAsin (Promega Corp., Madison, WI), 0.1MIgg of
random hexamer primers (Boehringer Mannheim Biochemicals, In-
dianapolis, IN), and 400 U ofMoloney murineleukemiavirus reverse
transcriptase (Gibco/BRL, Gaithersburg, MD). RT was terminated
by heating at 950C for 10 min.
Qualitative analysis ofmRNA levels byRT-PCR. To answer ques-
tionsregardingpresenceofmRNA species, we usedPCRamplification
at 35 or 40 cycles. A lack ofproduct at these levels ofamplification
using specific primers generally indicates little or no expression ofthe
genestudied. However, quantitative comparisons between samples are
uncertain at these high cycle numbers, because the plateau ofexpan-
sion has usually been reached (22). Sequence-specific primers used
were designed to amplify selectively the messages coding for certain
FGFfamily members, FGFreceptors, andhumanbeta-actin(TableI).
I Ml ofcDNA prepared from THP-I cells was amplified at 40 cyclesas
previouslydescribed (22)usingaFGF, bFGF, andactinprimers. 1 Mlof
cDNA prepared from human arteries and vascular cell samples was
amplified at 35 cycles in 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCI2, 50
mM KCl, 0.2 mM each deoxyribonucleotide triphosphate, 0.25 Mg of
each primer, and 2.5 U of Taq polymerase (Boehringer Mannheim
Biochemicals). Each cycle included denaturation at 940C for 30 s,
annealingat620Cfor30s, andprimerextension at720Cfor30susing
a thermocycler (model 9600; Perkin-Elmer Cetus Corp., Norwalk,
CT). 10 Ml ofeach amplification mixture were electrophoresed on an
agarose gel and DNA bands visualized by ethidium bromide staining.
In all cases, the estimated sizes ofthe amplification products detected
corresponded well to the predicted sizes. Cloning into the plasmid
pCRIOOO (Invitrogen Corp., San Diego, CA) and sequencing by the
dideoxynucleotide chain termination method using an automated
DNA sequencer (model 373A; Applied Biosystems, San Jose, CA)
confirmed the identity of FGF-5 and FGF-7 PCR products. Similar
analysis of the PCR product obtained using the FGF-3 primer pair
indicated no correlation with FGF-3 mRNA. Therefore, dataobtained
using the FGF-3 primer pair are not reported.
Immunohistochemistry. Serialfrozensections(6Mm)werecutonto
poly-L-lysine coated slides and fixed in acetone. Incubation in 0.3%
hydrogen peroxide for20 minexhaustedendogenousperoxidaseactiv-
ity. For each antibody the dilution that yielded optimal specific stain-
ing was determined in pilot experiments. Primary antibodies were di-
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Figure 3. Human atheroma contain aFGF mRNA. This figure shows
results ofNorthern analysis. Five atherosclerotic plaquescontained
aFGF mRNA. Only one offive control human arteries (carotid ar-
tery, lane 1; aortas, lanes 2-4; coronary artery, lane 5) had compara-
ble levels ofthis message. The major transcript detected in human
tissues comigrated with the 4.3-kb species present in RNA from hu-
man SMC treated with PMA, used as a positive control. The 3.2-
and 2.7-kb transcripts, evident in the positive control, were visualized
in extractsofhuman tissues only atlongerexposures. The ethidium
bromide-stained gel (bottom) shows that equal amounts ofRNA had
been used for each sample.
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Figure 4. Expression ofbFGF and FGFR-l mRNA does not differ
between control and atherosclerotic arteries. This figure shows results
ofNorthern analysis. Expression ofbFGF mRNA and FGFR- I dffg
mRNA asdetected in six atherosclerotic plaques and three nonathero-
sclerotic human aortas. Lines at right mark the position ofthe 28S
rRNA; the region ofthe ethidium bromide-stained gel containing the
corresponding 28S band is shown at the bottom.
luted in PBS + 10% horse serum and applied to the sections for 1 h.
Following two washes in Tris-buffered saline (TBS) with 2% horse
serum,abiotinylatedsecondaryantibody( 1:100dilution;VectorLabo-
ratories, Burlingame, CA) directed against the species oforigin ofthe
primary antibody, wasapplied for 45 min. After two washeswith TBS
plus 2% horse serum and one in TBS alone, the ABC Elite solution
(ABC Elite kit, VectorLaboratories) wasapplied for45 min. The sub-
strate 3-amino-9-ethyl-carbazole yieldedabrown-redreactionproduct.
Sectionswerelightlycounterstainedwithmethylgreenorhematoxylin.
The following primary antibodies were used: affinity-purified rabbit
polyclonal anti-human aFGF(10Ag/ml;reference 23); mouse mono-
clonalanti-bovinebFGF(10 Ig/ml;Cat. no.05-117;UpstateBiotech-
nology Inc., LakePlacid, NY); mousemonoclonal anti-musclealpha-
actin, HHF35 (1:50dilution; Cat. no. MA-931;EnzoDiagnostics,New
York, NY); mouse monoclonal EBM-l 1 ( 1:4,000 dilution); mouse
monoclonal anti-human von Willebrand factor( 1:1,000dilution, cat.
no. M616; Dako Corp.). We also used Ulex europeus agglutinin I
( 1:800dilution;Cat. no. L-1060;VectorLaboratories)toidentifyendo-
thelial cells. Controls were performed using the sameconcentration of
species and isotype-matched antibodies; rabbit polyclonal Ig fraction
(Cat. no. X936; Dako Corp.) was used as control for the affinity-puri-
fied rabbit polyclonal anti-human aFGF antibody. These irrelevant
antibodies did not stain the specimens examined. An additional con-
trol for aFGF specificity involved the use ofa working dilution ofthe
affinity-purified anti-aFGF polyclonal serum after overnight preab-
sorption with a 100-fold molar excess ofhuman recombinant aFGF.
Stainingofsampleswiththisserumwascompletelyblocked.Compara-
tive examination ofserial sections stained with the above-mentioned
antibodies permitted colocalization of growth factors and cell types.
Weused asemiquantitative gradingsystem toanalyzetheimmunohis-
tochemical results. Two observers independently assigned a histologic
score to each specimen, indicating extent ofFGF staining associated
with agiven cell type (EC, SMC, macrophages) on a scale from 0 to 4.
Grade 0 indicated that the cell type examined did not stain for the
growth factor; grade 1 indicated positivity associated with less than
10% ofa given cell type; grade 2 indicated positivity of 10-30% ofa
given cell type; grade 3 indicated positivity of30-60% ofa given cell
type; and grade 4 indicated positivity ofmore than 60% ofagiven cell
type. Results ofthis analysis are presented as mean±SEM. Thegrades
assigned independently bybothobserversagreedwithin onegrade;dif-
ferences were resolved byjoint examination. Recent hemorrhage was
defined as macroscopically visible blood deposit withinthe vessel wall.
Old hemorrhage was defined as presence ofhemosiderin, detected us-
ingGomori's Prussian blue reaction identifying ferric ions.
Results
Culturedhuman ECandSMCexpress aFGF, bFGF, andlow
levels ofFGF-5 mRNA; SMCalso express FGF-7mRNA. We
screened cultured human EC and SMC for expression ofFGF
family members using RT-PCR at 35 cycles ofamplification
(Fig. 1). EC and SMC contained aFGF and bFGF mRNA, as
previously reported ( 17), as well as low amounts of FGF-5
mRNA. SMC also expressed FGF-7 mRNA (Fig. 1).
Control andatherosclerotic human arteries express aFGF,
bFGF, andFGF-7mRNA. Todeterminetherelevance ofthese
observations in vitro to human atherogenesis, we investigated
the expression ofFGF family members in control and athero-
sclerotic human arteries using RT-PCR analysis at 35 cycles
(Fig. 2). All control and atherosclerotic human arteries con-
tained aFGF, bFGF, and FGF-7 mRNA. Neither atheroscle-
rotic nor control arteries contained FGF-5 mRNA (Fig. 2),
although both EC and SMC expressed this mRNA species in
vitro (Fig. 1).
Humanatheroma contain moreaFGFmRNA thandocon-
trol human vessels, butsimilarlevels ofbFGFmRNA. Screen-
ingwithPCRat35 cyclesofamplification suggestedthataFGF
and bFGF mRNA were the most abundant FGFtranscripts in
human arteries. Becausequantitation ofmRNAlevelsby PCR
has certain limitations (22), we verified the expression of
aFGFandbFGFmRNAsinvasculartissuebyNorthernanaly-
sis. This technique detected aFGF mRNA in five of five
plaquestested, butonlyoneoffive control arterieshadcompa-
rable levelsofthismessage(Fig. 3). However, Northern analy-
sis showed no consistent difference in the steady state levels of
Figure 5. EC in vitro express FGFR-I
and FGFR-4 mRNA. SMC in vitro ex-
press FGFR-I and FGFR-2 mRNA.
This figure shows results of RT-PCR
analysis at 35 cycles. Wedetected ex-
pression of FGFR-I and -4 mRNAs in
human EC in vitro. Human SMC ex-
pressed FGFR-I and -2 transcripts.
Sources of positive control RNA were
human brain for FGFR-I and -2, and
human lung for FGFR-3 and -4.
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lTable I. Localization ofaFGF and bFGF in Human Atheroma
andNonatherosclerotic Arteries
SMC
EC microvessels Intima Media Macrophages
aFGF
plaque (n = 14) 3.3±0.7 0.5±0.6 1.1±0.7 2.0±0.6
control (n= 10) * 0 1.0±0.8 0.9±1.3
bFGF
plaque(n= 14) 1.5±1.1 1.1±1.0 2.6±0.6 0.5±0.6
control (n = 10) * 0.5±0.9 3.6±0.7 0
Data are mean+SEM, and represent the histologic scores (percent of
cellsstained)assigned asfollows: Grade 1, < 10%; grade 2, 10-30%;
grade 3, 30-60%; and grade 4, > 60%.
* Control arteries had no intimal microvessels.
bFGF mRNA in control (n = 3) vs. atherosclerotic arteries (n
= 6) (Fig. 4).
CulturedhumanECandSMCexpressFGFR-I mRNA. To
achieveamorecompleteunderstandingofthepotentialrespon-
sivenessofvascularcellsto FGFs, we studiedthe expression of
FGFR family members in human cultured vascular EC and
SMCusingRT-PCR(Fig. 5). SMCcontainedFGFR-l mRNA
andlowlevelsofFGFR-2 mRNA. ECexpressed FGFR-I tran-
scripts and low levels ofFGFR-4 mRNA.
Controlandatherosclerotic human arteries express similar
levels ofFGFR-J mRNA. All control and atherosclerotic sam-
ples examined contained similar levels ofFGFR-1 mRNA, as
detectedboth by RT-PCR(Fig. 6) and Northern analysis(Fig.
4). In addition, only control arteries contained FGFR-2
mRNA, while some control oratherosclerotic specimens con-
tained FGFR-4 mRNA (Fig. 6).
Neovascularization and hemorrhages within plaques. The
intima ofall plaques (n = 14) contained microvascular plexi.
+
z CONTROL z
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These vessels generally had a thin wall composed ofEC alone
orwith one ortwolayersofSMC(Fig. 7). Microvascularplexi
were found mainly at the base of plaque near the junction
between intima and media ( 15/15 samples), or near the ne-
crotic core (14/15 samples). These vessels localized within or
adjacentto areasofmacrophageinfiltration in 13/15 samples.
Nine plaques showed recent hemorrhages (9/15). All three
plaques examined with Gomori's test had signs ofold hemor-
rhages. Inallthreecases,thehemosiderindepositswerelocated
near microvessels within lesions (data not shown). The speci-
mensstudied showed no areas ofulceration orplaque rupture.
Distribution ofaFGFandbFGFinatheroscleroticandcon-
trol arteries. Because aFGF and bFGF mRNA were the most
abundantFGFtranscriptsinhumanarteries, weimmunolocal-
ized the corresponding proteins using specific antibodies. The
EC lining the luminal surface of plaques or control arteries
were sometimes incompletely preserved due to perioperative
manipulation, but whenever present stained foraFGFboth in
control and atherosclerotic arteries (Fig. 7 and 8). EC ofle-
sionalmicrovesselsconsistentlystainedforaFGF(Fig. 7,Table
II). Medial SMC stained weakly foraFGF inboth control and
atherosclerotic arteries (Figs. 7 and 8; Table II). Intimal SMC
in plaques had even less aFGF staining than medial SMC of
both control arteries and atheroma (Figs. 7 and 8; Table II).
Macrophage-rich areaswithinplaquesstainedforaFGFin 13/
15 atherosclerotic arteries (Fig. 7, Table II). Also, scattered
macrophages present in the thickened intima ofcontrol arter-
ies colocalized with aFGF protein, but with less intense stain-
ing (Table II).
Luminal EC, where preserved, stained for bFGF in both
control and atherosclerotic arteries (Figs. 8 and 9). EC of
plaque microvesselsinconsistently stainedforbFGFproteinin
12/ 15 samples(TableII). MedialSMCcolocalizedwithbFGF
in all control and atherosclerotic arteries (Figs. 8 and 9; Table
II). Basic FGF staining also coincided with microvascular
SMC of vasa vasorum (Fig. 9, Table II). However, intimal
SMC, identified by staining for muscle alpha-actin, often
PLAQUE
2 3 4 5 6 7
Figure 6. Expression of mRNA for FGFR family
members in human carotid plaques and control
arteries. This figure shows results of RT-PCR
analysis at 35 cycles. All control and atheroscle-
rotic arteriesexamined contained FGFR-I tran-
scripts. Only control arteries had FGFR-2 mRNA,
while FGFR-4 mRNA expression was inconsis-
tent. Sources ofpositive control RNA were as in-
dicated for Fig. 5.
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Figure 8. Control human arteries contain scarce aFGF protein but high levels ofbFGF protein. Serial sections ofnonatheroscierotic human ar-
teries oriented to show the lumen in the upper portion ofeach picture. Immunodetectable aFOF, identified by staining with the affinity-purified
rabbit polyclonal anti-human aFGF (10 yg/ml; reference 23) colocalized with luminal EC, recognized by staining with Ulex europeus agglutinin
I (not shown), and with scattered medial SMC ofhuman aorta, characterized by stainingwith HHF35 antibody (not shown). Substantial bEGE
protein, identified with a mouse monoclonal anti-bovine bFGF antibody (10 yg/ml), colocalized with EC and with medial SMC ofhuman
carotid (lower row; x100).
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Figure 9. Atherosclerotic plaques contain low levels ofbFGF protein. Serial sections of two different and representative plaques, oriented with
lumen on top and shown at x40 (upper row) or x 100 (lower row). Immunodetectable bFGF, identified with a mouse monoclonal anti-bovine
bFGF antibody (10 pg/ml), colocalized with luminal EC, recognized by staining with Ulex europeus agglutinin I (1:800 dilution). Areas with
intimal SMC, localized by muscle alpha-actin staining (not shown) contain little immunodetectable bFGF protein.
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11*stained less intensely for bFGF (Table II), and three plaques
lackedanyimmunoreactive bFGFprotein associatedwithinti-
mal SMC (3/15; Fig. 9). Basic FGF colocalized with macro-
phages within atherosclerotic plaques (6/15), but staining for
thisproteinwaslimitedtolessthan 10% ofcells(TableII). The
few intimal macrophages in control arteries did not stain for
bFGF (Table II).
THP-J cellsinduciblyexpressaFGFmRNA. BecauseaFGF
protein consistently colocalized with plaque macrophages, a
cell type not heretofore known to express this gene, we tested
whethermononuclearphagocytescouldexpresstheaFGFgene
in vitro. Monocytes, monocyte-derived macrophages, and
THP-1 cells, treated in vitro with PMA, IFN-gamma, LPS,
lysophosphatidylcholine, or PDGF-BB for up to 72 h con-
tained no aFGF mRNA (data not shown). However, pro-
longed treatment ( 14-17 d)ofTHP-1 cellswith PMAinduced
accumulation ofaFGF mRNA (Fig. 10). Unstimulated THP-
1 cells at days 0 or 17 ofculture did not contain this message.
PMA-treated THP-l cellsalso expressed bFGF mRNA atdays
7, 14, and 17 ofstimulation, whileunstimulatedTHP-l cellsat
days 0 and 17 lacked this message (Fig. 10). Two independent
experiments yielded similar results.
Discussion
Experimental studies in rats ( 13, 14) indicate a role forbFGF
in initiating medial SMC proliferation after balloon injury.
aFGF may also accelerate re-endothelialization and reduce in-
timal thickening after a similar type of injury (12). Despite
considerable interest in the role ofFGFs in vascular growth,
THP-1
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Figure10. Human monocytoid THP-l cells express aFGF and bFGF
genes inducibly in vitro. This figure shows results ofRT-PCR at 40
cycles ofamplification. THP-I cells were continuously stimulated
with PMA (100 nM) for up to 17 d to mimic macrophage differen-
tiation. Selective primers for aFGF, bFGF, and beta-actin were used.
Treatment with PMA induced expression ofaFGF mRNA at days 14
and 17, and ofbFGF mRNA at days 7, 14, and 17 ofstimulation.
Unstimulated cells at days 0 and 17 contained neither aFGF nor
bFGF transcripts. Human SMC treated with PMA served as a positive
control; equal volumes of the reaction mixture without addition of
cDNA provided negative controls (Blank). PCR products obtained
using beta-actin primers show that similar amounts ofcDNA were
used and similarly amplified.
there is little information available regardingthe presence and
distribution ofthese growth factors or oftheir receptors in ei-
ther normal ( 15, 16) or atherosclerotic ( 16) human arteries.
This study examined these issues to explore the potential roles
ofFGFs in human vessels, and tointegrate dataobtained from
animal studies with observations on human atherosclerosis.
Advanced human atheroma usually contain microvessels
that may contribute to plaque evolution or complication via
intraplaque hemorrhages (24-27). Human atherosclerotic tis-
sues contain thermolabile angiogenic activity (28). We found
that human atheroma contained more aFGF mRNA and pro-
tein than did uninvolved human arteries. We also observed a
prominent association between aFGF protein and plaque re-
gions rich in microvessels, suggesting that this growth factor
participates in neovascularization oflesions. However, protein
distribution doesnotnecessarilyimplybiologicalactivity,espe-
cially in the case ofFGFs, which may be sequestered within
cells or by binding to extracellular heparan sulfate proteogly-
cans. The observation that the introduction ofconstructs that
direct the expression ofa secreted form ofaFGF promotes de
novoformation ofintimalmicrovessels(7)providesdirectevi-
dence thatthisgrowth factor can cause intimal angiogenesis in
vivo. Furthermore, Gordonand colleagues havedemonstrated
that dividing cells within human atheroma, identified by posi-
tive staining for the proliferating cell nuclear antigen (29), lo-
calizepreferentially inareasofmicrovascularization, anindica-
tion ofongoing growth factor activity in these loci (Gordon,
D., unpublished observations). Hemosiderin deposits located
near intimal microvessels, as reported by us and others (24,
25), suggest the occurrence of prior hemorrhage from these
structures. The newly formed vascular channels may be prone
to rupture; consequent thrombosis in situ might activate
thrombin-mediated events, such as SMC proliferation. Plaque
microvessels also provide a large surface area, which can pro-
mote further recruitment ofleukocytes viaexpression ofadhe-
sion molecules (30) and/or production ofchemoattractants,
and thus contribute to the evolution ofthe atherosclerotic le-
sion.
We found that regions in plaqueswith abundant aFGFand
microvessels often contained numerous macrophages. The co-
localization ofmacrophages andimmunoreactive aFGFin hu-
man atheroma was intriguing, since mononuclear phagocytes
are notknown to produce aFGF. Weinvestigated thispossibil-
ity using THP-1 cells, a homogeneous and well characterized
monocytoid cell line adapted to long-term culture. Interest-
ingly, induction of aFGF mRNA did not occur upon short-
term exposure to a wide range of stimuli, but required long-
term treatment with PMA. Phorbol esters promote THP-l dif-
ferentiation into macrophage-like cells (19) and induce
expression ofFGF genes in other human cell types (17, 18).
The requirement for prolonged stimulation may mimic in vi-
tro the shift in phenotype ofmononuclear phagocytes occur-
ring during atherogenesis in vivo. Macrophages in lesions may
be far removed from blood monocytes, as a result ofchronic
stimulationbyavarietyofpathophysiologically relevantmedia-
tors, modeled here by phorbol ester. The inducible expression
ofthe aFGF gene by a monocytoid cell line, together with the
observation that in vivo plaque macrophages localize near or
within areas rich in microvessels, suggests that these cells may
contribute to the neovascularization characteristic ofadvanced
atherosclerotic lesionsby local release ofangiogenic substances
such as aFGF.
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(31-33), such as bFGF (33), in response to various stimuli
(31 ). Our analysis ofhuman atherosclerotic samples showed
less consistent colocalization of bFGF than of aFGF with
plaque macrophages. However, we found substantial bFGFin
the endothelium and in the medial layer ofnonatherosclerotic
human arteries, as previously reported in normal rat arteries
(13). Balloon withdrawal injury to the normal rat carotid
causes intimal thickening resembling in some respects the re-
stenoticlesion ofhuman arteriesafterangioplasty. Experimen-
taldataimplicatebFGFintheinitiation ofmedial SMCprolif-
eration during this process in rats (11, 13). However, because
human atheroma contain scarce bFGF protein, as indicated
hereandelsewhere(16),ballooninjurytoanadvancedhuman
lesion may release less bFGF than would injury to normal rat
arteries. Our finding ofscant bFGF protein in human athero-
sclerotic intima parallels the low levels ofbFGF found in inti-
mal lesions ofballoon-injured rat carotid arteries (13).
Although human atherosclerotic arteriescontainedlessim-
munoreactive bFGF protein than control vessels, levels of
bFGF mRNA did notdiffer significantly. Several factorscould
account forthis apparent disparity between bFGF mRNA and
protein levels. For example, the regulation ofbFGF synthesis
inatherosclerotic lesionsmightbeposttranscriptional. Alterna-
tively, ongoing biosynthesis ofbFGF, reflected in mRNA lev-
els, may notcontribute substantially to thesteady statelevel of
bFGFprotein, as the bulk ofthisgrowth factor present in nor-
mal arteries may represent preformed intracellular or matrix-
bound protein. The low level ofbFGF protein documented in
plaques could derive from depletion or consumption ofbFGF
stores rather than from reduced biosynthesis.
With respect to more recently recognized forms ofFGFs,
we found consistent expression ofFGF-7 mRNA both in cul-
tured SMC and in humanarteries. FGF-7, also known askera-
tinocytegrowthfactor(34), selectivelystimulatesproliferation
ofepithelial cells (35) buthas no mitogenic activity on human
EC (35) or SMC (Rubin, J., personal communication). Fur-
thermore, we found that human vascular cells and arten uv
not contain mRNA forthe FGFR-2 splice variant that specifi-
cally binds FGF-7 (Winkles, J., unpublished observations).
Therefore, the biological relevance of FGF-7 within human
arteries remains uncertain.
Growth factorresponsiveness requiresexpression ofan ap-
propriate receptor. FGFRs constitute a family encoded by at
least fourdifferent genes (36-39). Alternative splicingpermits
the assembly of multiple isoforms of each receptor (9, 10).
Furthermore, each FGFR can bind two or more FGFs, with
graded affinity. FGFR-1, encoded by theflg gene, can bind
both aFGF and bFGF. We found consistent expression of
FGFR-1 mRNA in all control and atherosclerotic arteries ex-
amined. Several investigators have explored the use oftoxins
conjugated toFGFsasastrategy to preventexcessiveprolifera-
tion of SMC after arterial injury. Our data suggest that this
approachmightnotspareECandSMCinnormalhumanarter-
ies, a point that merits further investigation.
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